Asset Details
Do you wish to reserve the book?
A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild‐to‐moderate plaque psoriasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild‐to‐moderate plaque psoriasis
Do you wish to request the book?
A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild‐to‐moderate plaque psoriasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild‐to‐moderate plaque psoriasis
2024
Overview
Introduction Psoriasis is an immune‐mediated inflammatory skin disease. First‐line topical treatments include steroids, calcineurin inhibitors, vitamin D analogs, and anthralin. Recently, novel topical therapeutics like tapinarof and roflumilast have emerged with unique anti‐inflammatory mechanisms and promising efficacy profiles. Materials and methods This review utilized PubMed, SCOPUS, and Web of Science databases to identify recent studies on tapinarof and roflumilast. Criteria focused on efficacy, safety profiles, and therapeutic roles in psoriasis treatment. Results Four primary literature articles were identified for tapinarof and five for roflumilast. Both drugs demonstrated strong efficacy with minimal adverse events in treating mild‐to‐moderate plaque psoriasis. Tapinarof showed more frequent but mild adverse effects, while roflumilast had less frequent but more severe side effects. Discussion Tapinarof and roflumilast offer once‐daily dosing and successful treatment in restricted areas, potentially enhancing patient adherence. Cost remains a limiting factor, necessitating future comparative studies to evaluate the efficacy, safety, and cost‐effectiveness between the two drugs. Conclusion Tapinarof and roflumilast present promising topical treatments for psoriasis, showing efficacy and manageable safety profiles. Further research is crucial to fully elucidate their comparative benefits and drawbacks in clinical practice.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Aminopyridines - administration & dosage
/ Aminopyridines - adverse effects
/ Aminopyridines - therapeutic use
/ Benzamides - administration & dosage
/ Benzamides - adverse effects
/ Benzamides - therapeutic use
/ Cyclopropanes - administration & dosage
/ Cyclopropanes - adverse effects
/ Cyclopropanes - therapeutic use
/ Dermatologic Agents - administration & dosage
/ Dermatologic Agents - adverse effects
/ Dermatologic Agents - therapeutic use
/ Drugs
/ efficacy
/ Humans
/ Original
/ Phosphodiesterase 4 Inhibitors - administration & dosage
/ Phosphodiesterase 4 Inhibitors - adverse effects
/ Phosphodiesterase 4 Inhibitors - therapeutic use
/ Safety
